Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks; K. M. Kerr; J. Menis; T. S. Mok; U. Nestle; A. Passaro; D. Planchard; S. Peters; E. F. Smit; B. J. Solomon; G. Veronesi; M. Reck; ESMO Guidelines Committee; ESMO Guidelines Committee

doi:10.1016/j.annonc.2022.12.013

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

L. E. Hendriks, K. M. Kerr, J. Menis, T. S. Mok, U. Nestle, A. Passaro, D. Planchard, S. Peters, E. F. Smit, B. J. Solomon, G. Veronesi, M. Reck, ESMO Guidelines Committee, ESMO Guidelines Committee^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

148 Downloads (Pure)

Original language	English
Pages (from-to)	358-376
Number of pages	19
Journal	Annals of Oncology
Volume	34
Issue number	4
DOIs	https://doi.org/10.1016/j.annonc.2022.12.013
Publication status	Published - 1 Apr 2023

Keywords

ESCAT
ESMO Clinical Practice Guideline (CPG)
ESMO-MCBS
non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)
treatment
targeted therapy
immunotherapy
RANDOMIZED PHASE-III
QUALITY-OF-LIFE
PACLITAXEL DOUBLET CHEMOTHERAPY
RESPONSE EVALUATION CRITERIA
PLATINUM-BASED CHEMOTHERAPY
PEMETREXED PLUS CISPLATIN
SPECIFIED FINAL ANALYSIS
INDIVIDUAL PATIENT DATA
ELDERLY-PATIENTS
2ND-LINE TREATMENT

Access to Document

10.1016/j.annonc.2022.12.013

Full TextFinal published version, 1.25 MBLicence: Taverne

Cite this

Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Planchard, D., Peters, S., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., ESMO Guidelines Committee, & Guidelines Committee, ESMO. (2023). Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(4), 358-376. https://doi.org/10.1016/j.annonc.2022.12.013

@article{7f71c7dbb1194345a38e5b383cefe585,

title = "Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up",

keywords = "ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, immunotherapy, RANDOMIZED PHASE-III, QUALITY-OF-LIFE, PACLITAXEL DOUBLET CHEMOTHERAPY, RESPONSE EVALUATION CRITERIA, PLATINUM-BASED CHEMOTHERAPY, PEMETREXED PLUS CISPLATIN, SPECIFIED FINAL ANALYSIS, INDIVIDUAL PATIENT DATA, ELDERLY-PATIENTS, 2ND-LINE TREATMENT",

author = "Hendriks, {L. E.} and Kerr, {K. M.} and J. Menis and Mok, {T. S.} and U. Nestle and A. Passaro and D. Planchard and S. Peters and Smit, {E. F.} and Solomon, {B. J.} and G. Veronesi and M. Reck and {ESMO Guidelines Committee} and {Guidelines Committee}, ESMO",

year = "2023",

month = apr,

day = "1",

doi = "10.1016/j.annonc.2022.12.013",

language = "English",

volume = "34",

pages = "358--376",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "4",

}

Hendriks, LE, Kerr, KM, Menis, J, Mok, TS, Nestle, U, Passaro, A, Planchard, D, Peters, S, Smit, EF, Solomon, BJ, Veronesi, G, Reck, M, ESMO Guidelines Committee & Guidelines Committee, ESMO 2023, 'Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up', Annals of Oncology, vol. 34, no. 4, pp. 358-376. https://doi.org/10.1016/j.annonc.2022.12.013

TY - JOUR

T1 - Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

AU - Hendriks, L. E.

AU - Kerr, K. M.

AU - Menis, J.

AU - Mok, T. S.

AU - Nestle, U.

AU - Passaro, A.

AU - Planchard, D.

AU - Peters, S.

AU - Smit, E. F.

AU - Solomon, B. J.

AU - Veronesi, G.

AU - Reck, M.

AU - ESMO Guidelines Committee

AU - Guidelines Committee, ESMO

PY - 2023/4/1

Y1 - 2023/4/1

KW - ESCAT

KW - ESMO Clinical Practice Guideline (CPG)

KW - ESMO-MCBS

KW - non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC)

KW - treatment

KW - targeted therapy

KW - immunotherapy

KW - RANDOMIZED PHASE-III

KW - QUALITY-OF-LIFE

KW - PACLITAXEL DOUBLET CHEMOTHERAPY

KW - RESPONSE EVALUATION CRITERIA

KW - PLATINUM-BASED CHEMOTHERAPY

KW - PEMETREXED PLUS CISPLATIN

KW - SPECIFIED FINAL ANALYSIS

KW - INDIVIDUAL PATIENT DATA

KW - ELDERLY-PATIENTS

KW - 2ND-LINE TREATMENT

U2 - 10.1016/j.annonc.2022.12.013

DO - 10.1016/j.annonc.2022.12.013

M3 - Article

C2 - 36669645

SN - 0923-7534

VL - 34

SP - 358

EP - 376

JO - Annals of Oncology

JF - Annals of Oncology

IS - 4

ER -